Impressive response to oral metronomic chemotherapy in ovarian cancer

Abstract

Ovarian cancer detected in late stages due to early no symptoms or vague symptoms and hence recurrence is rule in majority of patients. Treatment of recurrent disease is based on whether patient had platinum sensitive or platinum refractory disease. Despite various chemotherapy options available in recurrent ovarian cancer, many patients die from disease progression. Despite the availability of PARP inhibitors in the maintenance setting, high costs make this out of reach of many deserving patients. Oral metronomic chemotherapy might be reasonable cheaper alternative for patients who cannot afford the standard treatment given the promising and hypothesis-generating results from this case series.

Keywords

• Ovarian cancer
• Oral metronomic chemotherapy